Medicinova Inc

NASDAQ:MNOV  
2.59
+0.08 (+3.19%)
Products, Regulatory, Earnings Announcements

MediciNova Announces Results From Phase 2 Trial Of Treatment For Hospitalized COVID-19 Patients At Risk For ARDS

Published: 06/08/2022 12:54 GMT
Medicinova Inc (MNOV) - Medicinova Announces Positive Top-line Results From Phase 2 Clinical Trial of Mn-166 (ibudilast) in Hospitalized Covid-19 Patients at Risk for Acute Respiratory Distress Syndrome.
Medicinova Inc - Trial Achieved Statistical Significance for One of Co-primary Endpoints.
Medicinova Inc - Trial Also Achieved Statistical Significance for Proportion of Subjects Discharged From Hospital.
Medicinova Inc - Trial Achieved Statistical Significance for Proportion of Subjects Free of Respiratory Failure.
Medicinova Inc - There Were No Serious Adverse Events Related to Mn-166 (ibudilast).
Medicinova Inc - There Were Two Deaths in Placebo Group and No Deaths in Mn-166 (ibudilast) Group.
Medicinova Inc - Plan to Discuss Results of Study With FDA and Get Feedback to Determine Next Steps.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.11

More details on our Analysts Page.